{Reference Type}: Review
{Title}: Primary Central Nervous System Vasculitis Following Alemtuzumab Treatment for Multiple Sclerosis: A Case Report and Literature Review.
{Author}: Varela L;Pappolla A;Heriz A;Márquez R;Vega O;Christiansen S;Rugiero M;Midaglia L;Salerno A;Tintoré M;Rovira À;
{Journal}: Neurologist
{Volume}: 28
{Issue}: 4
{Year}: Jul 2023 1
{Factor}: 1.524
{DOI}: 10.1097/NRL.0000000000000480
{Abstract}: <B>BACKGROUND: </B>Cerebral vasculitides are often devastating conditions that require immediate diagnosis and treatment.<BR><B>METHODS: </B>We report a pathologically proven clinical case of primary central nervous system vasculitis in a 50-year-old man with a diagnosis of relapsing-remitting multiple sclerosis after alemtuzumab therapy, which required additional immunosuppression to control this life-threatening condition.<BR><B>CONCLUSIONS: </B>In patients presenting subacute neurological deterioration after alemtuzumab therapy, primary central nervous system vasculitis should be considered as a differential diagnosis among other autoimmune conditions.